The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Δημοσίευση

Generic Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial.

TitleGeneric Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial.
Publication TypeJournal Article
Year of Publication2015
AuthorsNtalas, I. V., Kalantzi K. I., Tsoumani M. E., Vakalis J. N., Vasilakopoulos V., Vardakis K., Vemmos K. N., Voukelatou M., Giannakoulas G., Giatrakos I., Giogiakas V., Goumas G., Dimoulis N., Draganigos A., Efthimiadis I., Thoma M., Kazakos E., Kipouridis N., Konstantinou S., Bourdakis A., Nikolopoulos D., Peltekis L., Prokopakis N., Sinteles I., Stroumbis C. S., Terzoudi K., Tsilias K., Xaraktsis I., Charmpas C., Hatziathanasiou G., Christogiannis Z., Panagiotakos D. B., Goudevenos J. A., & Tselepis A. D.
JournalCurr Vasc Pharmacol
Volume13
Issue6
Pagination809-18
Date Published2015
ISSN1875-6212
Abstract

BACKGROUND: The aim of the present interim analysis was to compare the clinical efficacy and safety of the generic clopidogrel besylate (CB) with the innovator clopidogrel hydrogen sulphate (CHS) salt in patient groups eligible to receive clopidogrel.METHODS: A 2-arm, multicenter, open-label, phase 4 clinical trial. Consecutive patients (n=1,864) were screened and 1,800 were enrolled in the trial and randomized to CHS (n=759) or CB (n=798). Primary efficacy end point was the composite of myocardial infarction, stroke or death from vascular causes, and primary safety end point was rate of bleeding events as defined by Bleeding Academic Research Consortium (BARC) criteria.RESULTS: At 6-months follow-up no differences were observed between CB and CHS in primary efficacy end point (OR, 0.80; 95% CI, 0.37 to 1.71; p=0.57). Rates of BARC-1,-2,-3a and -5b bleeding were similar between the two study groups whereas no bleeding events according to BARC-3b, -3c, -4 and -5a were observed in either CHS or CB group.CONCLUSION: The clinical efficacy and safety of the generic CB is similar to that of the innovator CHS salt, thus, it can be routinely used in the secondary prevention of atherothrombotic events for a period of at least 6 months. (Salts of Clopidogrel: Investigation to ENsure Clinical Equivalence, SCIENCE study Clinical Trials.gov Identifier: NCT02126982).

Alternate JournalCurr Vasc Pharmacol
PubMed ID25782408

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.